Total Payments
$79,590
2024 Payments
$14,516
Companies
16
Transactions
174
Medicare Patients
4,372
Medicare Billing
$3.1M
Payment Breakdown by Category
Other$58,511 (73.5%)
Consulting$9,350 (11.7%)
Travel$6,741 (8.5%)
Food & Beverage$4,989 (6.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $58,500 | 29 | 73.5% |
| Consulting Fee | $9,350 | 4 | 11.7% |
| Travel and Lodging | $6,741 | 20 | 8.5% |
| Food and Beverage | $4,989 | 120 | 6.3% |
| Honoraria | $10.87 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan, Inc. | $46,644 | 62 | $0 (2021) |
| Astellas Pharma US Inc | $27,278 | 33 | $0 (2024) |
| ABBVIE INC. | $3,552 | 6 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $663.89 | 20 | $0 (2024) |
| Genentech USA, Inc. | $433.82 | 16 | $0 (2024) |
| Alimera Sciences, Inc. | $254.47 | 13 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $158.38 | 4 | $0 (2019) |
| Valeant Pharmaceuticals North America LLC | $151.65 | 4 | $0 (2017) |
| Alcon Vision LLC | $139.56 | 1 | $0 (2022) |
| Coherus Biosciences Inc. | $84.34 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14,516 | 27 | Astellas Pharma US Inc ($11,475) |
| 2023 | $16,241 | 31 | Astellas Pharma US Inc ($15,803) |
| 2022 | $1,138 | 16 | ABBVIE INC. ($686.97) |
| 2021 | $3,995 | 8 | Allergan, Inc. ($3,920) |
| 2020 | $6,977 | 10 | Allergan, Inc. ($6,920) |
| 2019 | $2,945 | 12 | Allergan Inc. ($2,818) |
| 2018 | $11,501 | 27 | Allergan Inc. ($11,180) |
| 2017 | $22,277 | 43 | Allergan Inc. ($21,806) |
All Payment Transactions
174 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/19/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $30.87 | General |
| Category: Ophthalmology | ||||||
| 11/04/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 10/28/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $27.15 | General |
| Category: Ophthalmology | ||||||
| 10/28/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 10/24/2024 | Astellas Pharma US Inc | Izervay (Drug) | Travel and Lodging | Cash or cash equivalent | $15.94 | General |
| Category: Ophthalmology | ||||||
| 10/18/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $98.87 | General |
| Category: Ophthalmology | ||||||
| 10/17/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $133.33 | General |
| 09/26/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: Ophthalmology | ||||||
| 09/16/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Ophthalmology | ||||||
| 09/16/2024 | Astellas Pharma US Inc | Izervay (Drug) | Travel and Lodging | Cash or cash equivalent | $1,307.36 | General |
| Category: Ophthalmology | ||||||
| 09/16/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $122.88 | General |
| Category: Ophthalmology | ||||||
| 09/16/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $42.26 | General |
| Category: Ophthalmology | ||||||
| 08/06/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $900.00 | General |
| Category: Ophthalmology | ||||||
| 07/23/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $30.70 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: Ophthalmology | ||||||
| 06/12/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $29.41 | General |
| Category: Ophthalmology | ||||||
| 06/11/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 05/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $36.76 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/20/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Ophthalmology | ||||||
| 05/20/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $10.83 | General |
| Category: Ophthalmology | ||||||
| 05/01/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $29.19 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 04/10/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $9.16 | General |
| Category: Ophthalmology | ||||||
| 03/20/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| Category: Ophthalmology | ||||||
| 03/14/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $150.51 | General |
| Category: Ophthalmology | ||||||
| 02/28/2024 | Astellas Pharma US Inc | Izervay (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,097 | 8,142 | $1.6M | $889,802 |
| 2022 | 9 | 1,068 | 3,047 | $1.5M | $769,983 |
| 2021 | 10 | 1,087 | 3,023 | $1.4M | $689,944 |
| 2020 | 10 | 1,120 | 3,375 | $1.5M | $747,565 |
Total Patients
4,372
Total Services
17,587
Medicare Billing
$3.1M
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 107 | 896 | $947,572 | $607,283 | 64.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 21 | 5,220 | $226,956 | $151,884 | 66.9% |
| 67028 | Injection of drug into eye | Office | 2023 | 161 | 608 | $159,705 | $56,127 | 35.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 252 | 346 | $71,238 | $32,184 | 45.2% |
| 92134 | Imaging of retina | Office | 2023 | 366 | 790 | $106,253 | $23,418 | 22.0% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 47 | 123 | $18,795 | $6,483 | 34.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 53 | 53 | $30,475 | $6,236 | 20.5% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 79 | 94 | $29,140 | $5,846 | 20.1% |
| 92250 | Photography of the retina | Office | 2023 | 11 | 12 | $1,287 | $342.21 | 26.6% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 89 | 882 | $897,435 | $621,190 | 69.2% |
| 67028 | Injection of drug into eye | Office | 2022 | 164 | 657 | $269,569 | $59,773 | 22.2% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 250 | 329 | $60,878 | $29,819 | 49.0% |
| 92134 | Imaging of retina | Office | 2022 | 348 | 772 | $107,823 | $23,302 | 21.6% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2022 | 68 | 230 | $34,300 | $11,911 | 34.7% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2022 | 12 | 12 | $48,540 | $10,136 | 20.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 58 | 58 | $33,350 | $6,849 | 20.5% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 67 | 93 | $28,309 | $5,715 | 20.2% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2022 | 12 | 14 | $5,180 | $1,288 | 24.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 75 | 724 | $736,670 | $527,650 | 71.6% |
| 67028 | Injection of drug into eye | Office | 2021 | 159 | 682 | $279,458 | $60,674 | 21.7% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 277 | 368 | $67,959 | $35,262 | 51.9% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 355 | 779 | $107,563 | $24,407 | 22.7% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2021 | 81 | 314 | $46,300 | $16,908 | 36.5% |
| 67042 | Removal of membrane from the retina, pars plana approach with removal of internal limiting membrane of retina | Facility | 2021 | 13 | 14 | $56,630 | $12,439 | 22.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 64 | 64 | $36,800 | $8,061 | 21.9% |
About Dr. Matthew Witmer, MD
Dr. Matthew Witmer, MD is a Ophthalmology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/14/2007. The National Provider Identifier (NPI) number assigned to this provider is 1235321167.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Witmer, MD has received a total of $79,590 in payments from pharmaceutical and medical device companies, with $14,516 received in 2024. These payments were reported across 174 transactions from 16 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($58,500).
As a Medicare-enrolled provider, Witmer has provided services to 4,372 Medicare beneficiaries, totaling 17,587 services with total Medicare billing of $3.1M. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist
- Location Rochester, NY
- Active Since 08/14/2007
- Last Updated 07/11/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1235321167
Products in Payments
- OZURDEX (Drug) $41,143
- Izervay (Drug) $13,725
- EYLEA (Biological) $393.39
- EYLEA AFLIBERCEPT INJECTION (Biological) $214.86
- YUTIQ (Drug) $188.17
- Vabysmo (Drug) $184.24
- Centurion (Device) $139.56
- STELLARIS PC (Device) $112.05
- Lucentis (Biological) $112.04
- Cimerli (Biological) $106.11
- ENVISTA (Device) $94.64
- ILUVIEN (Drug) $74.28
- BEOVU (Drug) $70.20
- EYLEA HD (Biological) $55.64
- RETISERT (Drug) $45.20
- STELLARIS (Device) $37.26
- Luxor (Device) $27.18
- Iluvien (Drug) $23.60
- VISUDYNE (Drug) $20.88
- VABYSMO (Drug) $19.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Rochester
Paul Hartman, Md, MD
Ophthalmology — Payments: $355,012
Ophthalmology $355,012
Malav Joshi, M.d, M.D
Ophthalmology — Payments: $295,274
Ophthalmology $295,274
Sophie Bakri, M.d, M.D
Ophthalmology — Payments: $268,408
Ophthalmology $268,408
Dr. Scott Macrae, M.d, M.D
Ophthalmology — Payments: $74,108
Ophthalmology $74,108
Dr. Muhammad Bhatti, Md, MD
Ophthalmology — Payments: $55,971
Ophthalmology $55,971
Dr. O Zazulak, Md, MD
Ophthalmology — Payments: $49,357
Ophthalmology $49,357